oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression of Ephb2 and Ephb4 in breast carcinoma
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Örebro University, School of Medical Sciences. Department of Pathology, Örebro Medical Center Hospital, Örebro, Sweden.ORCID iD: 0000-0001-6881-237X
Show others and affiliations
2004 (English)In: Pathology and Oncology Research, ISSN 1219-4956, E-ISSN 1532-2807, Vol. 10, no 1, 26-33 p.Article in journal (Refereed) Published
Abstract [en]

Eph receptor tyrosine kinases and their cell-surface-bound ligands, the ephrins, play key roles in diverse biological processes. Eph receptors comprise the largest family of receptor tyrosine kinases consisting of eight EphA receptors (with five corresponding ephrinA ligands) and six EphB receptors (with three corresponding transmembrane ephrinB ligands). Originally identified as neuronal pathfinding molecules, EphB receptors and ephrinB ligands are later proved to be crucial regulators of vasculogenesis and embryogenesis. More studies indicate that Eph receptors are involved in angiogenesis and tumorigenesis. This study aimed to investigate the expression of EphB2 and EphB4 in breast carcinomas. Semiquantitative RT-PCR and immunohistochemistry were used to examine the expression patterns of EphB2 and EphB4. Clinicopathological and survival correlations were statistically analyzed in a series of 94 breast carcinomas, 9 normal specimens and 4 breast carcinoma cell lines. 1(1%), 16(17%), 29(31%), 48(51%) of the 94 tumors were negative, weak, moderate and strong EphB2 protein expression, respectively. 6(6%), 27(29%), 28(30%), 33(35%) of the tumors were negative, weak, moderate and strong EphB4 expression, respectively. Both EphB2 and EphB4 RTPCR products could be detected in all specimens. Increased EphB2 protein expression was negatively associated with overall survival, and there was a trend that increased EphB2 protein expression was correlated with shorter disease free survival, while EphB4 protein expression was associated with histological grade and stage. EphB4 membrane staining was increased with S phase fraction and associated with DNA aneuploidy. These findings indicate that both EphB2 and EphB4 are involved in the development of breast cancer and that both molecules could be potential predictive markers.

Place, publisher, year, edition, pages
Budapest, Hungary: Arányi Lajos Foundation , 2004. Vol. 10, no 1, 26-33 p.
Keyword [en]
EphB2, EphB4, breast carcinoma, RT-PCR, immunohistochemistry
National Category
Cancer and Oncology Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:oru:diva-49508DOI: 10.1007/BF02893405ISI: 000220420000005PubMedID: 15029258Scopus ID: 2-s2.0-1942536189OAI: oai:DiVA.org:oru-49508DiVA: diva2:914907
Available from: 2016-03-27 Created: 2016-03-25 Last updated: 2016-04-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Karlsson, Mats G
By organisation
School of Medical Sciences
In the same journal
Pathology and Oncology Research
Cancer and OncologyClinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 219 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf